ASRM Responds to Supreme Court Ruling on Mifepristone
For Immediate Release
Washington, DC – “We are thrilled that a unanimous Supreme Court has rejected the ideologically driven lower court decisions on access to mifepristone, reversing an action that has already endangered too many people in need of healthcare. The decision further affirms the robust drug safety program at the United States FDA.
We are pleased that Americans will retain access to this essential medication, and that physicians will be able to provide evidence-based care for their patients. We hope that this marks a turning point in how our nation’s decision-makers evaluate access to reproductive healthcare.”
For almost a century, the American Society for Reproductive Medicine (ASRM) has been the global leader in multidisciplinary reproductive medicine research, ethical practice, and education. ASRM impacts reproductive care and science worldwide by creating funding opportunities for advancing reproduction research and discovery, by providing evidence-based education and public health information, and by advocating for reproductive health care professionals and the patients they serve. With members in more than 100 countries, the Society is headquartered in Washington, DC, with additional operations in Birmingham, AL. www.asrm.org
For media inquiries regarding this press release contact:
Sean Tipton
ASRM Chief Advocacy and Policy Officer
E: stipton@asrm.org
Anna Hovey
Advocacy Engagement Specialist
E: ahovey@asrm.org
J. Benjamin Younger Office of Public Affairs
726 7th St. SE
Washington, DC 20003
Tel: (202) 863-2494
Fertility in the News
ASRM Launches National Campaign in Support of Reproductive Rights Ballot Measures
ASRM launches a national campaign supporting reproductive rights ballot measures in 10 states with ads, endorsements, and voter engagement efforts.
Fertility Care Gets Important Win in California
ASRM celebrates California's SB 729, expanding IVF coverage for same-sex couples and singles, advancing equitable fertility care access.